Therapy News and Research

RSS

Mountain River Physical Therapy chooses Clinicient's PracticeInsight cloud-based EMR and billing software

Clinicient Inc., a leader in outpatient rehabilitation business solutions, today announced that Mountain River Physical Therapy, a premier provider of personalized orthopedic, sports and industrial rehabilitation in West Virginia, Pennsylvania, Ohio, Virginia and Florida, selected Clinicient's PracticeInsight cloud based electronic medical record (EMR) and billing software.

7 Jun 2015

PALOMA3 supports palbociclib use in advanced breast cancer

Advanced breast cancer patients who have failed prior endocrine treatment may receive a progression-free survival benefit if palbociclib is added to fulvestrant, a phase III trial indicates.

5 Jun 2015

Shorter washout period during transition from natalizumab supported

A prematurely halted trial provides support for a relatively short washout period when transitioning patients with relapsing–remitting multiple sclerosis from natalizumab to fingolimod.

5 Jun 2015

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

The All Wales Medicines Strategy Group has recommended Daklinza (daclatasvir) for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. The recommendation is specifically for patients with advanced liver disease, for whom treatment options can be limited.

5 Jun 2015

New UT Arlington study finds that household items play significant role in infant's motor skill development

Toys, appliances, and even a sofa and coffee table can impact the way or when a baby first crawls, walks or achieves other growth milestones, but a new UT Arlington study finds that many parents are unaware of the significant role household items play in their infant's motor skill development.

5 Jun 2015

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Infants and young children living with HIV will finally have access to an improved formulation of an antiretroviral (ARV) treatment, following the U.S. Food and Drug Administration's tentative approval last week of lopinavir/ritonavir (LPV/r) oral pellets developed by the Indian generic company Cipla.

5 Jun 2015

Researchers identify immune system marker that drives therapy-resistant prostate cancer

You are a patient who has just been treated for a serious illness but neither you nor your doctor knows how likely it is that you -- in comparison with other patients -- will actually be helped by the treatment. This is often the situation with prostate cancer, one of the deadliest and most highly prevalent cancers. While hormone therapy can help, patient responses vary widely, and it's still unclear why some types of prostate cancer seem to be resistant to the therapy.

5 Jun 2015

Scientists identify new agent to combat tuberculosis

According to figures of the World Health Organization, some 8.7 million people contracted tuberculosis in 2012 and this disease is fatal for approximately 1.3 million people throughout the world each year. One of the main problems is that the tuberculosis pathogens have become resistant to the antibiotics used to fight them.

5 Jun 2015

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced an independent data monitoring committee (IDMC) has recommended the continuation of the company’s pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) following the first of three planned interim data analyses.

5 Jun 2015

Research shows how social network analysis can help identify cancer biomarkers

The advent of online social networks has led to the rapid development of tools for understanding the interactions between members of the network, their activity, the connections, the hubs and nodes. But, any relationships between lots of entities, whether users of Facebook and Twitter, bees in a colony, birds in a flock, or the genes and proteins in our bodies can be analyzed with the same tools.

5 Jun 2015

Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Seattle Children's today announced the opening of patient enrollment for the first clinical research trial of the drug Tumor Paint BLZ-100, which is designed to improve surgical outcomes in children with brain tumors – the most common solid tumor cancer in kids.

5 Jun 2015

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.

5 Jun 2015

Boston Scientific announces European launch of Precision Novi SCS System

Boston Scientific announces the European launch of the Precision Novi Spinal Cord Stimulator (SCS) System at the International Neuromodulation Society in Montreal, Canada. The 16-contact primary cell device has CE Mark for the treatment of chronic pain, and is the smallest high-capacity primary cell device currently available.

5 Jun 2015

$Elotuzumab boosts response in relapsed, refractory multiple myeloma$

Elotuzumab boosts response in relapsed, refractory multiple myeloma

Addition of the immunostimulatory antibody elotuzumab to the combination of lenalidomide and dexamethasone improves progression-free survival and the overall response rate in patients with relapsed or refractory multiple myeloma, research suggests.

4 Jun 2015

Dexcom® announces follow App is now available for Android devices

Continuous glucose monitoring is considered the most significant breakthrough in diabetes management in the past 40 years...

4 Jun 2015

Rhythm announces initiation of two setmelanotide Phase 2 trials for treatment of PWS, POMC-null obesity

Rhythm announced today the initiation of two Phase 2 clinical trials focused on evaluating the safety and effectiveness of setmelanotide (RM-493), the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of Prader-Willi Syndrome (PWS) and POMC-null obesity.

4 Jun 2015

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21").

4 Jun 2015

Cyberonics announces results for fourth quarter and fiscal year 2015

Cyberonics, Inc. today announced results for the fourth quarter and fiscal year ended April 24, 2015.

4 Jun 2015

Better treatment, prevention strategies still needed for opportunistic infections related to AIDS

Although treatment advances have dramatically reduced deaths from opportunistic infections related to AIDS, a new study drawing on 30 years of data from more than 20,000 patients in San Francisco suggests there is still ample room to improve. About a third--35 percent--of AIDS patients diagnosed with their first opportunistic infection from 1997 to 2012 in that city died within five years, according to the study, published in the Journal of Infectious Diseases.

4 Jun 2015

EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

To date, there is no drug approved for medical therapy of chordoma patients. Supporting research for chordoma (a very rare cancer arising from the skull base or the spine and affecting only one person in a million per year) was the focus of talks that took place on 30 April 2015 at the European Medicines Agency in London. The workshop was attended by patients, oncologists, pathologists, regulators, statisticians and industry representatives.

4 Jun 2015

Therapy News and Research

Mountain River Physical Therapy chooses Clinicient's PracticeInsight cloud-based EMR and billing software

PALOMA3 supports palbociclib use in advanced breast cancer

Shorter washout period during transition from natalizumab supported

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

New UT Arlington study finds that household items play significant role in infant's motor skill development

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Researchers identify immune system marker that drives therapy-resistant prostate cancer

Scientists identify new agent to combat tuberculosis

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Research shows how social network analysis can help identify cancer biomarkers

Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Boston Scientific announces European launch of Precision Novi SCS System

Elotuzumab boosts response in relapsed, refractory multiple myeloma

Dexcom® announces follow App is now available for Android devices

Rhythm announces initiation of two setmelanotide Phase 2 trials for treatment of PWS, POMC-null obesity

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Cyberonics announces results for fourth quarter and fiscal year 2015

Better treatment, prevention strategies still needed for opportunistic infections related to AIDS

EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News